Compare Gilead Sciences, Inc. (GILD) vs Manchester United PLC (MANU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Manchester United PLC — how do they compare? Gilead Sciences, Inc. trades at $134.79 (market cap $163.51B), while Manchester United PLC trades at $22.22 (market cap $3.86B). The key difference: Gilead Sciences, Inc. is far larger — about 42.4× Manchester United PLC's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | MANU | |
|---|---|---|
Market Cap | $163.51B | $3.86B |
Sector | Health | Media |
52-Week High | $155.80 | $23.53 |
52-Week Low | $108.22 | $15.10 |
Enterprise Value | $178.05B | $4.78B |
Dividend Yield | 2.49% | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Manchester United (MANU) trades at $22.24, up 0.86% with neutral technical signals. The company shows improving fundamentals with revenue growth to $667M in 2025 and recent Champions League qualification driving future revenue potential. However, profitability remains challenged with negative net margins and ROE. The stock faces mixed analyst sentiment with 40% buy ratings amid ongoing stadium development plans and ownership uncertainty.
Investment outlook balances stadium expansion upside against persistent profitability challenges. The $1.6B stadium project represents long-term value creation, but current negative earnings and high debt levels require careful monitoring. Near-term catalysts include Champions League revenue and potential ownership changes, while execution risks and competitive pressures remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →
